Fluvoxamine, a commonly prescribed selective serotonin reuptake inhibitor (SSRI), significantly reduced fatigue in long COVID patients during a randomized clinical trial. Researchers enrolled 399 adults and found that the low-cost antidepressant meaningfully improved both fatigue severity and overall quality of life compared with placebo, establishing one of the first pharmacological interventions with demonstrated benefit for this debilitating post-viral condition.
Long COVID fatigue affects millions worldwide, leaving patients unable to work or perform basic daily activities. The condition persists months or years after initial SARS-CoV-2 infection and resists most existing treatments. Fluvoxamine's mechanism in long COVID remains unclear, though SSRIs modulate serotonin and possess anti-inflammatory properties that may address underlying pathophysiology.
The trial's results matter because long COVID lacks FDA-approved treatments and patients often face dismissal from healthcare providers. Fluvoxamine costs pennies per dose and already appears on most formularies, making it immediately accessible compared with experimental therapies requiring years of development. The medication also carries a well-established safety profile from decades of depression and anxiety treatment.
Several limitations warrant consideration. The trial size, while adequate, remains modest for definitive treatment guidance. Researchers did not stratify results by long COVID subtype, so effectiveness may vary among patients with different symptom patterns. The study duration and long-term outcomes remain unclear from available reporting. Additionally, not all long COVID patients experience fatigue as their primary symptom, limiting fluvoxamine's applicability across the heterogeneous patient population.
The findings align with earlier observations that fluvoxamine may benefit COVID-19 patients, though mechanistic links remain speculative. Some researchers hypothesize the drug may reduce persistent viral remnants or restabilize dysregulated immune responses characteristic of long COVID